{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:06Z","timestamp":1791229626324,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background\/purpose<\/jats:title><jats:p>Graves\u2019 disease (GD) is the most common cause of thyrotoxicosis in children and adolescents. There is some debate regarding the optimal treatment and predicting factors of remission or relapse in children and adolescents with GD. In this study, we report a retrospective study of 195 children and adolescents with GD treated at a single tertiary institution in Korea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included children and adolescents with GD diagnosed before 19 years of age from January of 2000 to October of 2020. The diagnosis of GD was based on clinical features, high thyroxine (FT4), suppressed thyroid-stimulating hormone, and a positive titer of thyrotropin receptor antibodies. Remission was defined as maintenance of euthyroid status for more than six months after discontinuing antithyroid drug (ATD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 195 patients with GD were included in this study. The mean age at diagnosis was 12.9 \u00b1 3.2 years, and 162 patients (83.1%) were female. Among all 195 patients, five underwent thyroidectomy and three underwent radioactive iodine therapy. The mean duration of follow-up and ATD treatment were 5.9 \u00b1 3.8 years and 4.7 \u00b1 3.4 years, respectively. The cumulative remission rates were 3.3%, 19.6%, 34.1%, 43.5%, and 50.6% within 1, 3, 5, 7, and 10 years of starting ATD, respectively. FT4 level at diagnosis (P = 0.001) was predicting factors for remission [HR, 0.717 (95% CI, 0.591 \u2013 0.870), P = 0.001]. Methimazole (MMI)-related adverse events (AEs) occurred in 11.3% of patients, the most common of which were rash and hematologic abnormalities. Of a total of 26 AEs, 19 (73.1%) occurred within the first month of taking MMI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study, the cumulative remission rate increased according to the ATD treatment duration. Long-term MMI treatment is a useful treatment option before definite treatment in children and adolescents with GD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.687834","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T11:17:46Z","timestamp":1623669466000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-Term Antithyroid Drug Treatment of Graves\u2019 Disease in Children and Adolescents: A 20-Year Single-Center Experience"],"prefix":"10.3389","volume":"12","author":[{"given":"Ari","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga Young","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunseop","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seok","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yoon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Kyu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"B1","article-title":"Werner and Ingbar\u2019s the Thyroid","volume-title":"A Fundamental and Clinical Text","author":"Braverman","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMc081426","article-title":"Graves\u2019 Disease","volume":"359","author":"Metso","year":"2008","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2018.08.001","article-title":"Graves\u2019 Disease in Children","volume":"79","author":"Leger","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000430985","article-title":"Increasing Incidence of Juvenile Thyrotoxicosis in Denmark: A Nationwide Study, 1998-2012","volume":"84","author":"Havgaard Kjaer","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01252.x","article-title":"Increasing Incidence of Childhood Graves\u2019 Disease in Hong Kong: A Follow-Up Study","volume":"54","author":"Wong","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000241","article-title":"Pediatric Graves\u2019 Disease: Decisions Regarding Therapy","volume":"27","author":"Okawa","year":"2015","journal-title":"Curr Opin Pediatr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0477-x","article-title":"Controversies in the Management of Graves\u2019 Disease in Children","volume":"39","author":"Rivkees","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0222","article-title":"Antithyroid Drugs-The Most Common Treatment for Graves\u2019 Disease in the United States: A Nationwide Population-Based Study","volume":"26","author":"Brito","year":"2016","journal-title":"Thyroid"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.76.896.340","article-title":"Trends in Diagnostic and Therapeutic Criteria in Graves\u2019 Disease in the Last 10 Years","volume":"76","author":"Escobar-Jimenez","year":"2000","journal-title":"Postgrad Med J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2013.28.4.275","article-title":"The Diagnosis and Management of Hyperthyroidism in Korea: Consensus Report of the Korean Thyroid Association","volume":"28","author":"Moon","year":"2013","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1535","article-title":"Predicting the Likelihood of Remission in Children With Graves\u2019 Disease: A Prospective, Multicenter Study","volume":"121","author":"Glaser","year":"2008","journal-title":"Pediatrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jpeds.2013.12.047","article-title":"Graves Disease in Children: Thyroid-Stimulating Hormone Receptor Antibodies as Remission Markers","volume":"164","author":"Gastaldi","year":"2014","journal-title":"J Pediatr"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2016.21.2.70","article-title":"Predictive Factors for Early Response to Methimazole in Children and Adolescents With Graves Disease: A Single-Institute Study Between 1993 and 2013","volume":"21","author":"Hwang","year":"2016","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12167","article-title":"Thyroid-Stimulating Hormone Receptor Antibodies During Follow-Up as Remission Markers in Childhood-Onset Graves\u2019 Disease Treated With Antithyroid Drugs","volume":"36","author":"Wang","year":"2020","journal-title":"Kaohsiung J Med Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1944","article-title":"Positive Impact of Long-Term Antithyroid Drug Treatment on the Outcome of Children With Graves\u2019 Disease: National Long-Term Cohort Study","volume":"97","author":"Leger","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0612","article-title":"Antithyroid Drug Treatment for Graves\u2019 Disease in Children: A Long-Term Retrospective Study at a Single Institution","volume":"24","author":"Ohye","year":"2014","journal-title":"Thyroid"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.6.3986","article-title":"Predictors of Early Remission of Hyperthyroidism in Children","volume":"82","author":"Glaser","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13099","article-title":"Graves\u2019 Disease in Children: Long-Term Outcomes of Medical Therapy","volume":"85","author":"Rabon","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0842","article-title":"Predictors of Autoimmune Hyperthyroidism Relapse in Children After Discontinuation of Antithyroid Drug Treatment","volume":"93","author":"Kaguelidou","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000320028","article-title":"Pediatric Graves\u2019 Disease: Controversies in Management","volume":"74","author":"Rivkees","year":"2010","journal-title":"Horm Res Paediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0938","article-title":"Management of ENDOCRINE Disease: Arguments for the Prolonged Use of Antithyroid Drugs in Children With Graves\u2019 Disease","volume":"177","author":"Leger","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003420.pub4","article-title":"Antithyroid Drug Regimen for Treating Graves\u2019 Hyperthyroidism","author":"Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01054-1","article-title":"Safety of Long-Term Antithyroid Drug Treatment? A Systematic Review","volume":"42","author":"Azizi","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e20183034","DOI":"10.1542\/peds.2018-3034","article-title":"Long-Term Methimazole Therapy in Juvenile Graves\u2019 Disease: A Randomized Trial","volume":"143","author":"Azizi","year":"2019","journal-title":"Pediatrics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12902-020-00670-w","article-title":"Control of Graves\u2019 Hyperthyroidism With Very Long-Term Methimazole Treatment: A Clinical Trial","volume":"21","author":"Azizi","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0195","article-title":"Outcomes in Relapsed Graves\u2019 Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment","volume":"25","author":"Villagelin","year":"2015","journal-title":"Thyroid"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0652","article-title":"Long-Term Antithyroid Drug Treatment: A Systematic Review and Meta-Analysis","volume":"27","author":"Azizi","year":"2017","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2011.194","article-title":"Comparison of Methimazole and Propylthiouracil in the Management of Children and Adolescents With Graves\u2019 Disease: Efficacy and Adverse Reactions During Initial Treatment and Long-Term Outcome","volume":"24","author":"Sato","year":"2011","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1297\/cpe.26.1","article-title":"Relationship Between Dose of Antithyroid Drugs and Adverse Events in Pediatric Patients With Graves\u2019 Disease","volume":"26","author":"Yasuda","year":"2017","journal-title":"Clin Pediatr Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/thy.2006.0193","article-title":"Treatment for Childhood-Onset Graves\u2019 Disease in Japan: Results of a Nationwide Questionnaire Survey of Pediatric Endocrinologists and Thyroidologists","volume":"17","author":"Sato","year":"2007","journal-title":"Thyroid"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2569","article-title":"Analysis of 754 Cases of Antithyroid Drug-Induced Agranulocytosis Over 30 Years in Japan","volume":"98","author":"Nakamura","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2019.24.2.133","article-title":"Thyrotoxic Hypokalemic Periodic Paralysis Due to Grave\u2019s Disease in 2 Adolescents","volume":"24","author":"Rho","year":"2019","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04365.x","article-title":"Hepatotoxicity and Cutaneous Reactions After Antithyroid Drug Administration","volume":"77","author":"Otsuka","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1954","article-title":"Comparative Effectiveness of Therapies for Graves\u2019 Hyperthyroidism: A Systematic Review and Network Meta-Analysis","volume":"98","author":"Sundaresh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.10.6922","article-title":"Thyrotoxicosis in Prepubertal Children Compared With Pubertal and Postpubertal Patients","volume":"85","author":"Lazar","year":"2000","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.687834\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T11:17:50Z","timestamp":1623669470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.687834\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":37,"alternative-id":["10.3389\/fendo.2021.687834"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.687834","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"article-number":"687834"}}